HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection.

AbstractBACKGROUND:
Therapeutic practices for Cryptococcus neoformans infection in transplant recipients vary, particularly with regards to antifungal agent employed, and duration of therapy. The risk of relapse and time to recurrence is not known. We assessed antifungal treatment practices for cryptococcosis in a cohort of prospectively followed organ transplant recipients.
METHODS:
The patients comprised 83 transplant recipients with cryptococcosis followed for a median of 2.1 and up to 5.2 years.
RESULTS:
Patients with central nervous system infection (69% vs. 16%, P = 0.00001), disseminated infection (82.7% vs. 20%, P = 0.00001), and fungemia (29% vs. 8%, P = 0.046) were more likely to receive regimens containing amphotericin B than fluconazole as primary therapy. The use of fluconazole, on the other hand, was more likely for infection limited to the lungs (64% vs. 14%, P = 0.00002). Survival at 6 months tended to be lower in patients whose CSF cultures at 2 weeks were positive compared to those whose CSF cultures were negative (50% vs. 91%, P = 0.06). Maintenance therapy was employed in 68% (54/79) of the patients who survived >3 weeks. The median duration of maintenance therapy was 183 days; 55% received maintenance for > or = 6 months and 25% for >1 year. Relapse was documented in 1.3% (1/79) of the patients.
CONCLUSIONS:
A majority of the organ transplant recipients with cryptococcosis receive maintenance antifungal therapy for 6 months with low risk of relapse. These data can assist in trials to assess the optimal therapeutic approach and duration of therapy for cryptococcosis in transplant recipients.
AuthorsNina Singh, Olivier Lortholary, Barbara D Alexander, Krishan L Gupta, George T John, Kenneth J Pursell, Patricia Muñoz, Goran B Klintmalm, Valentina Stosor, Ramon Del Busto, Ajit P Limaye, Jyoti Somani, Marshall Lyon, Sally Houston, Andrew A House, Timothy L Pruett, Susan Orloff, Atul Humar, Lorraine A Dowdy, Julia Garcia-Diaz, Andre C Kalil, Robert A Fisher, Joseph Heitman, Shahid Husain
JournalTransplantation (Transplantation) Vol. 80 Issue 8 Pg. 1033-9 (Oct 27 2005) ISSN: 0041-1337 [Print] United States
PMID16278582 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Antifungal Agents
Topics
  • Adult
  • Aged
  • Antifungal Agents (therapeutic use)
  • Cryptococcosis (drug therapy)
  • Cryptococcus neoformans
  • Female
  • Humans
  • Male
  • Middle Aged
  • Opportunistic Infections (drug therapy)
  • Organ Transplantation
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: